George A. Eldridge - 09 Dec 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: Chief Financial Officer and Treasurer
Signature
/s/ George A. Eldridge
Issuer symbol
JBIO
Transactions as of
09 Dec 2022
Net transactions value
-$367,300
Form type
4
Filing time
13 Dec 2022, 17:00:12 UTC
Previous filing
09 Dec 2022
Next filing
08 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $8,494 +3,969 +202% $2.14* 5,929 09 Dec 2022 Direct F1
transaction AVTE Common Stock Sale $82,055 -3,386 -57% $24.23 2,543 09 Dec 2022 Direct F1, F2
transaction AVTE Common Stock Sale $14,711 -583 -23% $25.23 1,960 09 Dec 2022 Direct F1, F3
transaction AVTE Common Stock Options Exercise $21,400 +10,000 +510% $2.14* 11,960 12 Dec 2022 Direct F1
transaction AVTE Common Stock Sale $300,428 -10,000 -84% $30.04 1,960 12 Dec 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -3,969 -9.7% $0.000000 36,757 09 Dec 2022 Common Stock 3,969 $2.14 Direct F1, F5
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -7,094 -19% $0.000000 29,663 12 Dec 2022 Common Stock 7,094 $2.14 Direct F1, F5
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -2,906 -3.5% $0.000000 79,863 12 Dec 2022 Common Stock 2,906 $2.14 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $25.00, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.01 to $25.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.39, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F6 A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: Chief Financial Officer and Treasurer